Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
TCT 2025: SELUTION DeNovo: 1-Year Results Comparing Sirolimus Balloon vs DES in PCI
Author(s): Christian Spaulding Added: 2 weeks ago
TCT 2025 — Prof Christian M Spaulding (European Hospital Georges Pompidou & INSERM U 970, FR), principal investigator of the SELUTION DeNovo trial (M.A. Med Alliance S.A.; NCT04859985), joins us to share the one year results.This international, multicentre randomised trial enrolled over 3,300 patients at 50 sites across Europe and Asia to compare a sirolimus-eluting balloon (SEB) plus provisional… View more

Intervention
The XLIMIT Trial: XLIMUS® DES Shows Non-Inferiority to Synergy™ DES
Author(s): Luca Testa Added: 1 year ago
Dr Luca Testa (IRCCS Policlinico San Donato, IT) discusses the results of the XLIMIT Trial at the EuroPCR 2024 congress in Paris, France.In this video interview, Dr Testa explains the technology behind the XLIMUS® drug-eluting stent (Cardionovum®) and its benefits. He also reviews the XLIMIT Trial, detailing the study design, selection criteria and clinical outcomes.Specifically, the 6 to 9… View more

Intervention
Author(s): Byoung Geol Choi , Seung-Woon Rha , Se Yeon Choi , et al Added: 1 year ago

Anticoagulation
EuroPCR 24: The ABILITY Study
Author(s): Roxana Mehran Added: 1 year ago
EuroPCR 24 - Dr Roxana Mehran (Mount Sinai Hospital, US) outlines the findings of the ABILITY Global Diabetes study onsite at EuroPCR 2024.The ABILITY study (NCT04236609) aimed to evaluate the efficacy and safety of the Abluminus DES+ Sirolimus Eluting Stent System (SES) as compared to the XIENCE Everolimus Eluting Coronary Stent System in diabetic patients eligible for percutaneous coronary… View more

Intervention
The Hybrid Approach in CAD with Restore® DEB
Author(s): Alfonso Ielasi Added: 1 year ago
In this comprehensive video series, Dr Alfonso Ielasi (IRCCS Ospedale Galeazzi Sant'Ambrogio, IT) delves into the approach of using Restore® Drug-Eluting Balloon (DEB) in treating Coronary Artery Disease (CAD). View more

Intervention
Oral P2Y12 Inhibitors and Drug Interactions
Author(s): Elisabetta Bigagli , Jacopo Angelini , Alessandro Mugelli , et al Added: 5 months ago

Anticoagulation

Prevention & Chronic Conditions
EuroPCR 25: BIOADAPTOR RCT 3Y Outcomes
Author(s): Shigeru Saito Added: 5 months ago
EuroPCR25 - Novel DynamX Bioadaptor demonstrates a sustained reduction of device-related events from six-month to three-year follow-up compared to drug-eluting stents (DES).We are joined by Dr Shigeru Saito (Shonan Kamakura General Hospital, Kamakura, JP) to discuss key findings from the BIOADAPTOR RCT trial (NCT04192747). This prospective, randomised controlled trial compared the ELX1805J … View more

Intervention

Vascular Disease and Surgery
Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19
Author(s): Andrea Di Lenarda , Nicola Ferri , Massimiliano Lanzafame , et al Added: 1 year ago

COVID-19

CV Disease in Special Populations
Consequences and Management of Excessive Ostial Stent Protrusion
Author(s): Arditya Damarkusuma Added: 1 year ago
In this video, Dr Arditya Damarkusuma (Universitas Gadjah Mada, ID) presents his case report on aorto-ostial lesions, recently published in ICR Journal.This case covers the restenosis of a markedly protruding stent at the right coronary ostium in a 54-year old man, and is unusual in its 10-year longevity. Intravascular ultrasound-guided in-stent restenosis intervention using a wire bumper… View more

Imaging & Diagnostics

Intervention
TCT 24: The ECLIPSE Trial
Author(s): Ajay J Kirtane Added: 1 year ago
TCT Conference 2024 - Routine use of orbital atherectomy system (OAS) did not improve minimal stent area (MSA) or target vessel failure (TVF) at one year compaared to conventional balloon angioplasty.Dr Ajay J Kirtane (Columbia University Medical Center and New York-Presbyterian Hospital, New York, US) joins us onsite at TCT Conference to discuss the findings from ECLIPSE (NCT03108456; Abbott… View more

Intervention